Rare Hematological Malignancies (Cancer Treatment and Research Series)

Advances in diagnostic techniques and therapeutic modalities have brought about significant progress in the management of many hematologic malignancies. For the practicing clinician these changes are occurring at a rapid rate and it is difficult to keep informed of all the new information. Therefore, most physicians focus on the major diagnostic and therapeutic changes in common cancers, and it is often a challenge to stay up to date on the advances in the less common malignancies. Furthermore, it is difficult to find the new information in a timely fashion when seeing patients with an uncommon or unusual hematologic malignancy. In this book, data on rare hematologic malignancies have been assembled to provide a concise resource for practicing oncologists.
Each chapter provides information on the biology of the various rare hematologic diseases but also focuses on the latest therapeutic advances. Because of the paucity of clinical trials in most of these diseases, the authors have not only summarized the literature but also provided their own expertise regarding management of patients.

Johns Hopkins Patients' Guide to Leukemia

Johns Hopkins Patients' Guide to Leukemia is a concise, easy-to-follow how to guide that puts you on a path to wellness by explaining leukemia treatment from start to finish. It guides you through the overwhelming maze of treatment decisions, simplifies the complicated schedule that lies ahead, and performs the task of putting together your plan of care in layman s terms. Empower yourself with accurate, understandable information that will give you the ability to confidently participate in the decision making about your care and treatment.

About The Series
Learning that you or someone you love has cancer is devastating, and feeling lost and powerless is a common immediate response. The Johns Hopkins patients’ guides are designed to alleviate your anxiety, empower you with information, and enable you to fully understand your treatment options. Each book in this series is dedicated to a specific type of cancer. The information is there to help lighten your burden and to assist you in becoming an active participant in your care. Cancer rarely allows us to take a diversion from life, and offering guidance on how to continue to live life while.

Leukemias: Principles and Practice of Therapy

Edited by experts from one of the world’s largest leukemia centers, this book provides information on the biology of the variety of leukemic disorders, up-to-date diagnostic testing and many new developments in therapy. Chapters covering new treatments present an outlook for the future and explain the rationale for ongoing clinical trials.
Topics include:

• Targeted therapy, e.g. tyrosine kinase inhibitors (Flt3, Aurora kinase inhibitors, kit inhibitors, BCR-ABL inhibitors)
• Ras inhibitors
• Epigenetic therapy (hypomethylaters and histone deacetylase inhibitors)
• Lenalidomide analogs
• New chemotherapy drugs, e.g. clofarabine, cloretazine, sapacitabine, forodesine
• Combinations of chemotherapy with kinase inhibitors (e.g. ALL induction protocols in combination with dasatinib or imatinib)
• New monoclonal antibodies (lumiliximab, humaxCD20, anti-CD40)
• Thrombopoietic agents

Leukemias: Principles and Practice of Therapy

• Includes practical information to guide you in challenging situations, such as treatment of elderly patients, pregnancy, relapsed and refractory disease.
• Incorporates chapters on supportive care and pharmacologic information about the most frequently used drugs in this area.

Product Details

• Hardcover: 456 pages
• Publisher: Wiley-Blackwell; 1 edition (December 21, 2010)
• Language: English
• ISBN-10: 1405182350
• ISBN-13: 978-1405182355
• Product Dimensions: 10.9 x 8.8 x 1.1 inches

Understanding Leukemias, Lymphomas and Myelomas 2nd Edition

A brand-new edition of the bestselling guide to hematologic malignancies. An international team of contributors come together to present all clinically relevant aspects of leukemias, lymphomas, and myelomas. Using clear terminology, the book discusses salient features, diagnostic procedures, prognosis, and treatments for these cancers.
Following on the successful steps of the first edition, this Second Edition covers:

• various types of leukemias, lymphomas, and myelomas
• utilizing stem cell transplantation
• side-effects of various treatments
• future prospects for leukemia, lymphoma, and myeloma
• targeted therapies and history of the cancers
• information and support sources for patients

Product Details

• Hardcover: 200 pages
• Publisher: Informa Healthcare; 2 edition (August 11, 2010)
• Language: English
• ISBN-10: 1841846945
• ISBN-13: 978-1841846941
• Product Dimensions: 9.6 x 7.4 x 0.6 inches

Leukaemia Diagnosis 4th Edition by Barbara J. Bain (Wiley-Blackwell) 2010

Leukaemias are a very heterogeneous group of diseases, which differ from each other in aetiology, pathogenesis, prognosis and responsiveness to treatment. Accurate diagnosis and classification are necessary for the identification of specific biological entities and underpin scientific advances in this field. The detailed characterization of haematological neoplasms is also essential for the optimal management of individual patients. Many systems for the classification of leukaemia have been proposed.
Between 1976 and 1999, a collaborative group of French, American and British haematologists (the FAB group) proposed a number of classifications, which became widely accepted throughout the world. In 2001, a quarter of a century after the first FAB proposals, a World Health Organization (WHO) expert group proposed an updated system for the classification of leukaemia and lymphoma incorporating clinical features, haematological and histological features, immunophenotyping and the results of cytogenetic and, to a lesser extent, molecular genetic analysis. In 2008 a further updating of the WHO classification incorporated new knowledge and gave a greater importance to molecular genetic features.
Leukaemia Diagnosis 4th Edition by Barbara J. Bain illustrate and explain how these many laboratory techniques are used for the diagnosis and classification of leukaemia and related disorders. This book discuss diagnosis and classification in a way that will be helpful to trainee haematologists and to laboratory scientists in haematology and related disciplines. However, this book also tried to provide a useful reference source and teaching aid for those who already have expertise in this field. In addition, cytogeneticists and molecular geneticists will find that this book enhances their understanding of the relationship of their disciplines to the diagnosis, classification and monitoring of leukaemia and related disorders.
As the diagnosis and classification of leukaemia comes to rely increasingly on sophisticated and expensive investigations there is a risk that some countries will be left behind. For the first time the author have therefore incorporated, as an appendix, some suggestions as to how leukaemia might be diagnosed in under-resourced laboratories. This may seem presumptuous from someone who has not worked in a developing country for more than 40 years but I thought that at least it should be attempted.
Since photographs have been taken of many different microscopes and exact magnifications differ slightly, magnifications of photomicrographs in this edition are given as the microscope objective used.

Contents
1 The Nature of Leukaemia, Cytology, Cytochemistry and the FAB Classification of Acute Leukaemia
2 Immunophenotyping and Cytogenetic/Molecular Genetic Analysis in Leukaemia and Related Conditions
3 Acute Leukaemia: Integration of Morphological, Immunophenotypic and Genetic Information and the WHO Classification
4 The Myelodysplastic Syndromes
5 Chronic Myeloid Leukaemias
6 Lymphoid Leukaemias of Mature T, B and Natural Killer Cells
Appendix: Leukaemia Diagnosis in Resource-Poor Countries
Index

Coding Companion for Oncology/ Hematology 2011

Consolidate the coding process with the one-stop resource developed exclusively for those who code for oncology and hematology. This comprehensive guide includes 2011 CPT and ICD-9-CM code sets specific to oncology and hematology in an easy-to-use, one-page format. Each page has the CPT code with its official description and a detailed illustration, as well as lay descriptions, coding tips, terminology, cross-coding, and national Medicare relative value units. Getting to the code information you need has never been so easy.

Product Details

• Spiral-bound: 300 pages
• Publisher: Ingenix; 2011 edition (December 15, 2010)
• Language: English
• ISBN-10: 1601514409
• ISBN-13: 978-1601514400

Hematopoietic Growth Factors in Oncology (Springer) 2011

The hematopoietic growth factors (HGFs) are an important class of biologic molecules which augment production and functional maturation of hematopoietic cells.
Hematopoietic Growth Factors in Oncology represents the latest in a series of texts in the Cancer Treatment and Research series edited by Dr. Steven T. Rosen. This volume brings under a single cover a discussion of the early discoveries, extensive preclinical and clinical investigation, and the validation of these efforts through the successful clinical extension of these discoveries into clinical hematology and oncology practice improving the treatment and quality of life of countless patients.
The text begins with an outstanding review of the biologic, physiologic, and pharmacologic underpinnings of the discoveries, laboratory studies, and early preclinical and clinical development of the hematopoietic growth factors from some of the actual pioneers in these fundamental studies.While the anticipation around development of early-acting hematopoietic growth factors has not been fully realized, developments in granulocyte colony-stimulating factors, the erythropoietic-stimulating agents, and the thrombopoietin factors have in many ways exceeded the expectations of many. The next three parts in this book then highlight the further clinical development and application of the three major categories of the hematopoietic growth factors, by individuals involved in both the pivotal studies and extended clinical trials that have further defined the efficacy and safety of these agents. Current recommendations for clinical application of the hematopoietic growth factors based on practice guidelines from major professional organizations are presented along with the evidence synthesis available on both efficacy and safety.
In the final part of this volume, a number of very important special considerations regarding the use of the hematopoietic growth factors are discussed including their often controversial role in management of patients with acute leukemia and the myelodysplastic syndromes, their efficacy and toxicity in older cancer patients, and the cost and cost-effectiveness of these agents in the prevention and treatment of hematologic complications exemplified by the use of G-CSF for the prevention of febrile neutropenia in patients receiving cancer chemotherapy. The authors emphasize that any comprehensive evaluation of benefits, harms and costs must consider not only the immediate reduction in risk of neutropenic complications in patients receiving cancer chemotherapy but also the potential long-term effects on disease control and survival when treatment intensity is sustained or enhanced with the adjunctive use of the myeloid growth factors.
In total, this represents the most comprehensive compilation available of preclinical and clinical experience related to the development, validation, and clinical application of the hematopoietic growth factors. The editors share the perspective of the individual authors that no aspect of cancer care deserves more attention as well as further clinical research than the treatment and prevention of life-threatening complications of cancer treatment.

Contents
Part I Background: Biology, Physiology, and Pharmacology
1 Introduction to the Hematopoietic Growth Factors
2 Early-Acting Hematopoietic Growth Factors: Biology and Clinical Experience
3 Granulocyte Colony-Stimulating Factors
4 Erythropoiesis-Stimulating Agents
5 Thrombopoietin Factors
Part II The Colony-Stimulating Factors
6 Cyclic and Chronic Neutropenia
7 The Myeloid Growth Factors
8 Meta-Analysis of Randomized Controlled Trials of Granulocyte Colony-Stimulating Factor Prophylaxis in Adult Cancer Patients Receiving Chemotherapy
9 Summary and Comparison of Myeloid Growth Factor Guidelines in Patients Receiving Cancer Chemotherapy
10 Granulocyte Colony-Stimulating Factors and Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome
Part III The Erythroid-Stimulating Agents
11 Do Erythropoietic-Stimulating Agents Relieve Fatigue? A Review of Reviews
12 Randomized Controlled Trials of the Erythroid-Stimulating Agents in Cancer Patients
13 Ten Years of Meta-analyses on Erythropoiesis-Stimulating Agents in Cancer Patients
14 Clinical Practice Guidelines for the Use of Erythroid-Stimulating Agents: ASCO, EORTC, NCCN
Part IV The Thrombopoietic Agents
15 Thrombocytopenia and Platelet Transfusions in Patients with Cancer
16 Romiplostim
17 Eltrombopag
Part V Special Considerations
18 The Hematopoietic Growth Factors in Acute Leukemia: US Perspective
19 The Hematopoietic Growth Factors in Acute Leukemia: A European Perspective
20 The Hematopoietic Growth Factors in theMyelodysplastic Syndromes
21 Hematopoietic Growth Factors in Older Cancer Patients
22 The Economics of the Hematopoietic Growth Factors
Index

Product Details

• Author: Gary H. Lyman and David C. Dale
• Hardcover: 433 pages
• Publisher: Springer; 1st Edition. (November 8, 2010)
• Language: English
• ISBN-10: 144197072X
• ISBN-13: 978-1441970725

Lanzkowsky: Manual of Pediatric Hematology & Oncology 5th Edition

This will be the fifth edition of successful clinical manual aimed at all practitioners treating children with cancer and blood diseases, such as leukemia, anemia, and bone marrow failure. As with previous editions, this edition will be a comprehensive book on patient management, replete with algorithms and flow diagrams on diagnosis and management. Its concise and easy-to-read format will enable readers to make accurate diagnoses and permit them to treat patients even if they have not had extensive previous hematologic or oncologic experience. It will contain a list of normal values at various ages in children, which is extremely useful as a reference in the management of patients.

Since the previous edition was written five years ago, there have been considerable advances particularly in the treatment and management of oncologic diseases in children. These oncology sections (approximately 40% of the book) will be entirely rewritten to incorporate all current protocols. In addition, advances in many other areas will require that all hematology sections of the book be updated.
 

The successful basic format and content of clinical manifestations, diagnosis and differential diagnosis will be maintained - as in previous editions, the editor will closely edit chapter content to maintain consistency in format, depth, and style. In addition to the core group of hematologists and oncologists from Schneider Children's Hospital, who contributed to the 4^th edition, the editor is inviting 15 new authors who are all experts from around the country - in order to keep up with the advances in management of hem/onc diseases. The book will reflect the 45+ years of practical experience by the editor as well as the extensive clinical experience and research expertise of the various contributors.

 

Key Feature

• Offers a concise, systematic approach to all pediatric hematologic and oncologic disorders in one reference manual
• Easy-to-read format: multiple tables, charts, and flow-diagrams for diagnosis and management of pediatric hematologic and oncologic disorders
• Clear presentation by practicing clinicians, who are also academic researchers, of recent developments in molecular genetics, cytogenetics, immunology, transplantation, and biochemistry to the extent that they have bearing on clinical practice

Benefits

• Practitioners responsible for the care of children with hem/onc diseases will save time going to one concise, authoritative source for diagnosis and treatment options, without having to wade through all the details in larger tomes on hematology or oncology, or in thousands of journal articles
• Residents will use it as a guide to prepare for board examinations in pediatric hematology/oncology, pediatrics, hematology, and oncology
• Practicing pediatricians, hematologists, oncologists, fellows, and pediatric nurses will use it a quick source for a second opinion in diagnosis and disease management when they are unable to consult with a pediatric hem/onc specialist
• Practicing pediatric hem/onc specialists will use the book as a "refresher course" and will appreciate the systematic approach
• For all practitioners, correct diagnosis (and therefore correct treatment) of oncologic and hematologic diseases depends on a strong understanding of the molecular basis for the disease

About the Author

Dr. Philip Lanzkowsky is Chief-of-Staff of the Schneider Children's Hospital. He is Chairman of the Department of Pediatrics, Chief of the Division of Pediatric Hematology-Oncology, Director of the Pediatric Residency Training Program and Professor of Pediatrics at the Albert Einstein College of Medicine. In 1994, he was appointed Executive Vice President for Medical Affairs and Medical Director of Long Island Jewish Medical Center. In 1999, he was appointed Vice President for the Children's Health Network of the North Shore-Long Island Jewish Health System. The author of four texts in pediatric hematology-oncology, Dr. Lanzkowsky has in excess of 270 scientific publications to his name. He is the U.S. editor of the international journal Pediatric Reviews and Communications, and is Editor-in-Chief of The Children's Hospital Quarterly and is a member of the editorial board of Social Work in Health Care.

Book Details 
 

• Hardcover: 1058 pages
• Publisher: Academic Press; 5 edition (October 7, 2010)
• Language: English
• ISBN-10: 0123751543
• ISBN-13: 978-0123751546
• Product Dimensions: 9.3 x 7.8 x 2.2 inches
• List Price: $149.95 

 

Harrison's Hematology and Oncology

The authority of Harrison's in a handy, full-color paperback devoted exclusively to Hematology and Oncology
Featuring the chapters on Hematology and Oncology that appear in the landmark Harrison's Principles of Internal Medicine, 17e, this compact clinical companion delivers all the latest knowledge in the field, backed by the scientific rigor and reliability that have defined Harrison's.
You'll find coverage that reflects the expertise of renowned editors and contributors -- presented in a carry-anywhere format that makes it ideal for the classroom, the wards, or the point of care. With its ease of use, indispensable diagnosis-speeding guidelines, and acclaimed state-of-the-art strategies, Harrison's Hematology and Oncology is a must for students and clinicians alike.
Harrison's Hematology and Oncology delivers:

• A unique single-source reference featuring hard-to-find integrated information on hematology and oncology
• Integration of pathophysiology with clinical management topics in each of the disease-oriented chapters
• Valuable content in print form from the acclaimed Harrison's 17e DVD
• 52 chapters written by physicians who have made seminal contributions in their areas of expertise
• 115 high-yield self-assessment Q&A for exam and board review, drawn from Harrison's Principles of Internal Medicine Self-Assessment and Board Review, 17e
• Complete coverage of need-to-know hematology and oncology topics, including the latest information on hematopoiesis, cancer cell biology, and cancer prevention
• Helpful appendix that highlights laboratory values of clinical importance

Everything you would expect from Harrison's tailored to your specialty
Condensed Table of Contents: The Cellular Basis of Hematopoiesis; Cardinal Manifestations of Hematologic Disease; Anemias; Myeloproliferative Disorders; Hematologic Malignancies; Disorders of Hemostasis; Biology of Cancer; Principles of Cancer Prevention and Treatment; Neoplastic Disorders; Endocrine Neoplasia; Remote Effects of Cancer; Oncologic Emergencies and Late Complications.
The Harrison’s specialty series is written by the same world-renowned author team who brought you Harrison’s Principles of Internal Medicine, 17e:
Anthony S. Fauci, MD; Eugene Braunwald, MD; Dennis L. Kasper, MD; Stephen L. Hauser, MD; Dan L. Longo, MD; J. Larry Jameson, MD, PhD; Joseph Loscalzo, MD, PhD

About the Author

Dan L. Longo, MD
Scientific Director, National Institute on Aging
National Institutes of Health
Bethesda and Baltimore, MD

Product Details

• Paperback: 788 pages
• Publisher: McGraw-Hill Professional; 1 edition (May 10, 2010)
• Language: English
• ISBN-10: 0071663355
• ISBN-13: 978-0071663359
• Product Dimensions: 10.7 x 8.4 x 1.3 inches

Concise Manual of Hematology and Oncology

The Concise Manual of Hematology and Oncology is a practice-oriented manual of medical oncology and hematology for day-to-day use in caring for patients’ hematologic and neoplastic diseases. It is founded on the longstanding experience of a large specialized university department accustomed to having to provide reliable advice in a broad range of circumstances. We have deliberately chosen not to give a comprehensive review of the various subjects but have instead focused on practical methods which have proven to be useful in our experience, with special emphasis on standardizing chemotherapy protocols.

Product Details

• Hardcover: 1004 pages
• Publisher: Springer; 1 edition (November 21, 2008)
• Language: English
• ISBN-10: 3540732764
• ISBN-13: 978-3540732761
• Product Dimensions: 9.5 x 6.3 x 1.7 inches

Acute Promyelocytic Leukemia: Molecular Genetics, Mouse Models and Targeted Therapy

Acute Promyelocytic Leukemia: Molecular Genetics, Mouse Models and Targeted Therapy (Current Topics in Microbiology and Immunology) by Pier Paolo Pandolfi and Peter K. Vogt is meant to summarize some of the most recent progress made in elucidating the pathogenesis of Acute Promyelocytic Leukemia (APL) and in the treatment of this form of leukemia. It is also meant to celebrate one of the most successful accomplishments in cancer research and contemporary biomedical research. APL was in fact regarded as an almost invariably fatal disease just a decade ago, while it is now considered a curable leukemia - if not cured - in many advanced cancer centers in the world. APL is perhaps the most compelling exmple to date of what could be done and will be done in the years to come in the combat and defeat of the cancer plague if appropriate ressources are made available to the scientific commnunity. This tremendous progress in APL research and treatment has been made possible through a number of seminal discoveries and by the concerted efforts of many labs worldwide that have raced and competed with each other, but also interacted and cooperated, to reach this remarkable goal. Many of these groups and investigators have contributed to this dedicated volume.

Book Details

• Hardcover: 276 pages
  
• Publisher: Springer; 1 edition (February 1, 2007)
  
• Language: English
  
• ISBN-10: 3540345922
  
• ISBN-13: 9783540345923
  
• Product Dimensions: 9.4 x 6.3 x 0.6 inches
  
• List Price: $129.00
  

Flow Cytometry and Immunohistochemistry for Hematologic Neoplasms

Flow Cytometry and Immunohistochemistry for Hematologic Neoplasms by Tsieh Sun is a detailed guide to the use of flow cytometry, immunohistochemistry, and molecular genetic techniques for diagnosis of hematologic neoplasms. Dr. Sun explains the principles of these techniques and demonstrates their utility in 39 clinical cases covering all important entities. Each case represents a comprehensive diagnostic approach including a clinical history and flow cytometric, immunohistochemical, and molecular genetic findings.
Abundant full-color illustrations show histologic sections, immunohistochemical stains, bone marrow, peripheral blood, and body fluid smears, and each case includes a complete set of flow cytometric histograms. Over 100 tables compare and differentiate the diagnostic features of similar diseases.

Living Through Leukemia: A Journey to Health

Living Through Leukemia: A Journey to Health by Louis George Whitehead provides a detailed account of the steps involved in battling this life-threatening disease, including chemotherapy, irradiation, and a bone-marrow transplant, followed by a long recovery period that is both physically and emotionally exhausting. The book is mostly factual and descriptive in its writing style, but Whitehead also touches on his spiritual strength and never wavering belief that he will survive, as well as the support from family and friends that helps him pull through the ordeal. He also discusses his experiences with lengthy hospitals stays and medical staff. Many are helpful and caring, but there are others who seem to forget that they are dealing with human beings and tend to treat patients as "cases," leaving the patient feeling lost and lonely in his quest for recovery.
Whitehead shares his feelings following his initial diagnosis and through the realization that a fatal outcome was possible. He also details the events and symptoms leading up to his courageous battle and describes the importance of both his friends and family in the struggle to get well and stay that way.
If you or someone close to you is living with leukemia or is facing the prospect of a bone-marrow transplant, Whitehead’s personal reflections will serve as encouragement on how to approach each day with a leveled patience and look ahead to a more hopeful time.

About the Author
Louis George Whitehead holds a master’s degree in journalism from South Dakota State University and is the author of two books. He currently works as a freelance writer, photographer, and Web designer in Brookings, South Dakota.

Book Details

• Paperback: 154 pages
  
• Publisher: iUniverse, Inc. (August 27, 2007)
  
• Language: English
  
• ISBN-10: 0595445225
  
• ISBN-13: 9780595445226
  
• Product Dimensions: 8.8 x 5.9 x 0.4 inches
  
• List Price: $14.95